Bullish
Krystal Biotech (KRYS) Is Up 13.1% After Strong Q1 Earnings And FDA Nod For At-Home Vyjuvek Use – Has The Bull Case Changed?
Krystal Biotech (KRYS) reported strong first-quarter 2026 results, with net income rising to US$55.93 million and EPS of US$1.83. The company also sec...